HDAC9 and breast carcinoma: The primary aim of this study was to elucidate the antitumour mechanism of 15a in breast cancer, providing valuable insights for further pharmacological investigations and enhancing our understanding of the biological activity of dual DNMT/HDAC inhibitors.